Антимюллеров гормон в дифференцировке, развитии и функции репродуктивной системы

Интеграция сведений о роли антимюллерова гормона (АМГ) в дифференцировке, развитии и функции репродуктивной системы позволяет заключить следующее. Половые клетки предопределяют биосинтез АМГ от зарождения до окончания функции репродуктивной системы. Вступление половых клеток в мейоз ограничивает синтез АМГ, обеспечивая его постоянный уровень в течение репродуктивной зрелости. С угасанием гаметогенеза синтез АМГ прекращается.

антимюллеров гормон (АМГ), половые клетки, репродуктивная система

1. Дедов И.И., Семичева Т.В., Петеркова В.А. Половое развитие детей: норма и патология. М: Медицина 2002; 232.

2. Устинкина Т.И. Общие вопросы эндокринологии мужской половой системы: структурно-функциональная организация, этиопатогенез недостаточности и основные формы нарушений половых желез. Пробл эндокринол 2007; 53: 6: 34-40.

3. Устинкина Т.И. Эндокринология мужской половой системы. Ст-Петербург: ЭЛБИ-СПб 2007; 160.

4. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Prog Horm Res 1953; 8: 379-418.

5. Picard J.Y., Josso N. Purification of testicular anti-Müllerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol 1984; 34: 23-29.

6. Picard J.Y., Benarous R., Guerrier D. et al. Cloning and expression of cDNA for anti-Müllerian hormone. Proc Natl Acad Sci USA 1986; 83: 5464-5468.

7. Cate R.L., Mattaliano R.J., Hession C. et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986; 45: 685-698.

8. Cohen-Haguenauer O., Picard J.Y., Mattei M.G. et al. Mapping of the gene for anti-Müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987; 44: 2-6.

9. Clarke T.R., Hoshiya Y., Yi S.E. et al. Müllerian Inhibiting Substance signaling uses a Bone Morphogenetic Protein (BMP)-like pathway mediated by ALK2 and induces Smad6 expression. Mol Endocrinol 2001; 15: 946-959.

10. di Clemente N., Wilson C., Faure E. et al. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol 1994; 8: 1006-1020.

11. Josso N., di Clemente N., Gouédard L. Anti-Mullerian hormone and its receptors. Mol Cell Endocrinol 2001; 179: 25-32.

12. Klattig J., Englert C. The Müllerian duct: recent insights into its development and regression. Sex Dev 2007; 1: 5: 271-278.

13. Sharpe R.M., McKinnell C., Kivlin C., Fisher J.S. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. Reproduction 2003; 125: 769-784.

14. Lee M.M., Donahoe P.K., Hasegawa T. et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81: 571-576.

15. La Marca A., Broekmans F.J., Volpe A. et al. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24: 9: 2264-2275.

16. di Clemente N., Josso N., Gouedard L., Belville C. Components of the anti-Mullerian hormone signaling pathway in gonads. Mol Cell Endocrinol 2003; 211: 9-14.

17. Visser J.A. AMH signaling: from receptor to target gene. Mol Cell Endocrinol 2003; 211: 65-73.

18. Wang P.Y., Protheroe A., Clarkson A.N. et al. Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci USA 2009; 106: 17: 7203-7208.

19. Lebeurrier N., Launay S., Macrez R.et al. Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin. J Cell Sci 2008; 121: 20: 3357-3365.

20. Young J., Rey R., Couzinet B. et al. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84: 2696-2699.

21. Young J., Rey R., Schaison G., Chanson P. Hypogonadotropic hypogonadism as a model of post-natal testicular anti-Müllerian hormone secretion in humans. Mol Cell Endocrinol 2003; 211: 1-2: 51-54.

22. Young J., Chanson P., Salenave S. et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90: 2: 724-728.

23. Boukari K., Meduri G., Brailly-Tabard S. et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. J Clin Endocrinol Metab 2009; 94: 5: 1818-1825.

24. Chemes H.E., Rey R.A., Nistal M.et al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells. J Clin Endocrinol Metab 2008; 93: 11: 4408-4412.

25. Lee M.M., Donahoe P.K., Silverman B.L. et al. Measurements of serum Müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336: 1480-1486.

26. Josso N., Belville C., di Clemente N., Picard J.Y. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Human Reprod Update 2005; 11: 351-356.

27. Belville C., Van Vlijmen H., Ehrenfels C. et al. Mutations of the anti-müllerian hormone gene in patients with persistent müllerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 2004; 18: 708-721.

28. Brandli D.W., Akbal C., Eugsster E.et al. Persistent Mullerian duct syndrome with bilateral abdominal testis: surgical approach and review of the literature. J Pediatr Urol 2005; 1: 6: 423-427.

29. Josso N., Picard J.Y., Rey R., di Clemente N. Testicular anti-Müllerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006; 3: 4: 347-358.

30. Wuerstle M., Lesser T., Hurwitz R. et al. Persistent mullerian duct syndrome and transverse testicular ectopia: embryology, presentation, and management. J Pediatr Surg 2007; 42: 12: 2116-2119.

31. Beheshti M., Churchill B.M., Hardy B.E. et al. Familial persistent müllerian duct syndrome. J Urol 1984; 131: 968-969.

32. Josso N. Paediatric applications of anti-Müllerian hormone research. 1992 Andrea Prader Lecture. Horm Res 1995; 43: 243-248.

33. Stuchi-Perez E.G., Lukas-Croisier C., De Castro M. et al. Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia. J Pediatr Endocrinol Metab 2000; 13: 605-612.

34. Rey R.A., Belville C., Nihoul-Fekete C. et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 1999; 84: 2: 627-631.

35. Rey R. Anti-Müllerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol 2005; 49: 1: 26-36.

36. Misra M., MacLaughlin D.T., Donahoe P.K., Lee M.M. The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. J Clin Endocrinol Metab 2003; 88: 787-792.

37. Martinez-Aguayo A., Rocha A., Rojas N. et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 12: 4583-4589.

38. Eldar-Geva T., Hirsch H., Benarroch F. et al. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur J Endocrinol 2009; 162: 2: 377-384.

39. Hirsch H.J., Eldar-Geva T., Benarroch F. et al. Primary testicular dysfunction is a major contributor to abnormal pubertal development in males with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94: 7: 2262-2268.

40. Mostafa T., Amer M.K., Abdel-Malak G. et al. Seminal plasma anti-Müllerian hormone level correlates with semen parameters but does not predict success of testicular sperm extraction (TESE). Asian J Androl 2007; 9: 265-270.

41. Sinisi A.A., Esposito D., Maione L. et al. Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Human Reprod 2008; 23: 5: 1029-1034.

42. Laven J.S., Mulders A.G., Visser J.A. et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 1: 318-323.

43. Broekmans F.J., Visser J.A., Laven J.S. et al. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008; 19: 9: 340-347.

44. Chen M.J., Yang W.S., Chen C.L. et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 4: 952-957.

45. Shebl O., Ebner T., Sommergruber M. et al. Antimullerian hormone serum levels in women with endometriosis: a case-control study. Gynecol Endocrinol 2009; 25: 11: 713-716.

46. Broer S.L., Mol B.W., Hendriks D., Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009; 91: 3: 705-714.

47. Fréour T., Mirallié S., Colombel A. et al. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris) 2006; 67: 6: 567-574.

48. La Marca A., Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxford) 2006; 64: 6: 603-610.